82 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK We are exposed to market risk related to changes in interest rates. As of December 31, 2024, we had cash and cash equivalents of $168.1 million, primarily invested in money market funds. As of December 31, 2023, we had cash and cash equivalents of $285.5 million, primarily invested in money market funds. Due to the nature of the cash equivalents, we do not believe that interest rate risk had a material impact on our consolidated financial statements. We do not believe that other market risks, like foreign currency exchange rate risk, had a significant impact on our results of operations for any periods presented herein. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm (PCAOB ID: 238) 83 Consolidated Financial Statements Consolidated Balance Sheets 85 Consolidated Statements of Operations and Comprehensive Loss 86 Consolidated Statements of Stockholders’ Equity 87 Consolidated Statements of Cash Flows 88 Notes to Consolidated Financial Statements 89

Kodiak Sciences 2024 Annual Report - Page 94 Kodiak Sciences 2024 Annual Report Page 93 Page 95